| A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases RC Coll, AAB Robertson, JJ Chae, SC Higgins, R Muñoz-Planillo, ... Nature medicine 21 (3), 248-255, 2015 | 2912 | 2015 |
| Emerging pathogenic links between microbiota and the gut–lung axis KF Budden, SL Gellatly, DLA Wood, MA Cooper, M Morrison, ... Nature Reviews Microbiology 15 (1), 55-63, 2017 | 1706 | 2017 |
| Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice JJ Fuster, S MacLauchlan, MA Zuriaga, MN Polackal, AC Ostriker, ... Science 355 (6327), 842-847, 2017 | 1543 | 2017 |
| Optical biosensors in drug discovery MA Cooper Nature reviews Drug discovery 1 (7), 515-528, 2002 | 1480 | 2002 |
| NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice AR Mridha, A Wree, AAB Robertson, MM Yeh, CD Johnson, ... Journal of hepatology 66 (5), 1037-1046, 2017 | 1141 | 2017 |
| Human monocytes engage an alternative inflammasome pathway MM Gaidt, TS Ebert, D Chauhan, T Schmidt, JL Schmid-Burgk, F Rapino, ... Immunity 44 (4), 833-846, 2016 | 929 | 2016 |
| Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice R Gordon, EA Albornoz, DC Christie, MR Langley, V Kumar, S Mantovani, ... Science translational medicine 10 (465), eaah4066, 2018 | 814 | 2018 |
| Natural product and natural product derived drugs in clinical trials MS Butler, AAB Robertson, MA Cooper Natural product reports 31 (11), 1612-1661, 2014 | 741 | 2014 |
| Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1β/NLRP3 inflammasome S Sano, K Oshima, Y Wang, S MacLauchlan, Y Katanasaka, M Sano, ... Journal of the American College of Cardiology 71 (8), 875-886, 2018 | 695 | 2018 |
| Genomic characterization of the uncultured Bacteroidales family S24-7 inhabiting the guts of homeothermic animals KL Ormerod, DLA Wood, N Lachner, SL Gellatly, JN Daly, JD Parsons, ... Microbiome 4 (1), 36, 2016 | 672 | 2016 |
| Global patient outcomes after elective surgery: prospective cohort study in 27 low-, middle-and high-income countries BJA: British Journal of Anaesthesia 117 (5), 601-609, 2016 | 669 | 2016 |
| Fix the antibiotics pipeline MA Cooper, D Shlaes Nature 472 (7341), 32-32, 2011 | 659 | 2011 |
| Biomarkers in chronic kidney disease: a review RG Fassett, SK Venuthurupalli, GC Gobe, JS Coombes, MA Cooper, ... Kidney international 80 (8), 806-821, 2011 | 642 | 2011 |
| Label-free screening of bio-molecular interactions MA Cooper Analytical and bioanalytical chemistry 377 (5), 834-842, 2003 | 612 | 2003 |
| Antibiotics in the clinical pipeline in 2013 MS Butler, MA Blaskovich, MA Cooper The Journal of antibiotics 66 (10), 571-591, 2013 | 607 | 2013 |
| Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-β and cognitive function in APP/PS1 mice C Dempsey, AR Araiz, KJ Bryson, O Finucane, C Larkin, EL Mills, ... Brain, behavior, and immunity 61, 306-316, 2017 | 595 | 2017 |
| T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4+ T cells G Arbore, EE West, R Spolski, AAB Robertson, A Klos, C Rheinheimer, ... Science 352 (6292), aad1210, 2016 | 584 | 2016 |
| K+ efflux-independent NLRP3 inflammasome activation by small molecules targeting mitochondria CJ Groß, R Mishra, KS Schneider, G Médard, J Wettmarshausen, ... Immunity 45 (4), 761-773, 2016 | 573 | 2016 |
| Metal complexes as a promising source for new antibiotics A Frei, J Zuegg, AG Elliott, M Baker, S Braese, C Brown, F Chen, ... Chemical science 11 (10), 2627-2639, 2020 | 544 | 2020 |
| Aminoglycoside antibiotics in the 21st century B Becker, MA Cooper ACS chemical biology 8 (1), 105-115, 2013 | 534 | 2013 |
Mark BlaskovichGroup Leader, Institute for Molecular Bioscience, The University of QueenslandVerified email at uq.edu.au
